Recent advances in siRNA delivery for cancer therapy using smart nanocarriers

Zhang, Penghui; An, Keli; Duan, Xili; Xu, Hao; Li, Fēi; Xu, Feng

doi:10.1016/j.drudis.2018.01.042

Cited by 87 publications

(59 citation statements)

References 100 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…RNA-based therapeutics, such as small interfering RNA (siRNA) and microRNA (miRNA), provide a promising approach to treat cancer by targeting specific proteins involved in the mechanism of proliferation, invasion, antiapoptosis, drug resistance, and metastasis [6,7]. miRNAs are small (17 to Pharmaceutics 2020, 12, 189 2 of 16 25 nucleotides) non-coding RNA molecules, which specifically interact with target messenger RNA (mRNAs), resulting in inhibited translation or mRNA cleavage and degradation [8].…”

Section: Introductionmentioning

confidence: 99%

Sphingomyelin-Based Nanosystems (SNs) for the Development of Anticancer miRNA Therapeutics

et al. 2020

View full text Add to dashboard Cite

Gene replacement therapy with oncosuppressor microRNAs (miRNAs) is a promising alternative to interfere with cancer progression. However, miRNAs are highly inefficient in a biological environment, hampering a successful translation to clinics. Nanotechnology can tackle this drawback by providing delivery systems able to efficiently deliver them to cancer cells. Thus, the objective of this work was to develop biocompatible nanosystems based on sphingomyelin (SM) for the intracellular delivery of miRNAs to colorectal cancer cells. We pursued two different approaches to select the most appropriate composition for miRNA delivery. On the one hand, we prepared sphingomyelin-based nanosystems (SNs) that incorporate the cationic lipid stearylamine (ST) to support the association of miRNA by the establishment of electrostatic interactions (SNs–ST). On the other hand, the cationic surfactant (DOTAP) was used to preform lipidic complexes with miRNA (Lpx), which were further encapsulated into SNs (SNs-Lpx). Restitution of miRNA145 levels after transfection with SNs-Lpx was related to the strongest anticancer effect in terms of tumor proliferation, colony forming, and migration capacity assays. Altogether, our results suggest that SNs have the potential for miRNA delivery to develop innovative anticancer therapies.

show abstract

Section: Introductionmentioning

confidence: 99%

Sphingomyelin-Based Nanosystems (SNs) for the Development of Anticancer miRNA Therapeutics

et al. 2020

View full text Add to dashboard Cite

show abstract

“…siRNA delivery technology has been developed in a remarkable technology, and it has been evaluated for treating diseases including cancer, hypercholesterolemia, and more . According to a report, approximately 20 clinical trials have been initiated by siRNA based therapeutics . At this stage, majority of the clinical trials being conducted involved in therapeutic applications are using the siRNA .…”

Section: Gene‐silencing Technology In Cancer Therapymentioning

confidence: 99%

“…65 According to a report, approximately 20 clinical trials have been initiated by siRNA based therapeutics. 66 At this stage, majority of the clinical trials being conducted involved in therapeutic applications are using the siRNA. 67,68 Currently, in a recent report from a phase 1 study on patients with refractory or relapsed solid cancer, Davis et al reported on phase 1 study for patients with refractory solid tumor that could be achieved by administering siRNA.…”

Section: Small Hairpin Rnasmentioning

confidence: 99%

Biodegradable polymers in gene‐silencing technology

Hosseinkhani

Domb

2019

Polymers for Advanced Techs

View full text Add to dashboard Cite

Small interfering RNAs (siRNAs) technology has shown great promise as a new class of therapeutics invention for treatment of cancer and other diseases. siRNA has been used extensively in blocking various genes and is presently being evaluated as a therapeutic for cancer and viral disease. Despite the excitement about this remarkable biological process for sequence specific gene regulation, the major limitations against the use of siRNAs‐based therapeutics are their rapid degradation by serum nuclease, poor cellular uptake, and rapid renal clearance following systemic delivery, off‐target effects, and induction of immune responses. Many researchers have tried to overcome these limitations with developing nuclease‐resistant chemically modified siRNAs and variety of synthetic and natural biodegradable lipids and polymers for siRNA delivery to enhance efficacy and safety profiles. An ideal siRNAs‐based delivery system must be clinically suitable, safe, and effective. This review discuss the recent progress of biodegradable polymers in siRNA delivery technology.

show abstract

“…siRNA RNA interference (RNAi) is a well understood mechanism in mammalian cells by which sequencespecific RNA molecules, such as siRNA, miRNA or shRNA, lead to targeting and cleaving complementary mRNA. 25) The discovery of RNAi has had a great impact on the development of novel therapeutic strategies for intractable diseases such as cancer, 26,27) viral infections, 28,29) and hereditary disorders. 3,30) In particular, siRNA-based therapy has demonstrated promising outcomes in clinical trials.…”

Section: Recent Advances In Oligonucleotide-based Therapy In Attr-fapmentioning

confidence: 99%

Recent Advances in Oligonucleotide-Based Therapy for Transthyretin Amyloidosis: Clinical Impact and Future Prospects

Hayashi

Jono

2018

Biological & Pharmaceutical Bulletin

View full text Add to dashboard Cite

Transthyretin (TTR) amyloidosis, also known as transthyretin-related familial amyloidotic polyneuropathy (ATTR-FAP), is a fatal hereditary systemic amyloidosis caused by mutant forms of TTR. Although conventional treatments for ATTR-FAP, such as liver transplantation (LT) and TTR tetramer stabilizer, reportedly halt the progression of clinical manifestation, these therapies have several limitations. Oligonucleotide-based therapy, e.g. small interfering RNA (siRNA)-and antisense oligonucleotides (ASOs)-based therapy, hold enormous potential for the treatment of intractable diseases such as ATTR-FAP, by specifically regulating the gene responsible for the disease. Clinical evidence strongly suggests that LT inhibits mutant TTR production, thus improving the manifestation of ATTR-FAP. Therefore, an oligonucleotide-based therapy for ATTR-FAP, which reduces the production of TTR by the liver, has recently been developed in preclinical and clinical studies. This review focuses on recent advances in oligonucleotide-based therapy and future prospects of next-generation oligonucleotide-based drugs for therapeutic use against ATTR-FAP.

show abstract

Recent advances in siRNA delivery for cancer therapy using smart nanocarriers

Cited by 87 publications

References 100 publications

Sphingomyelin-Based Nanosystems (SNs) for the Development of Anticancer miRNA Therapeutics

Sphingomyelin-Based Nanosystems (SNs) for the Development of Anticancer miRNA Therapeutics

Biodegradable polymers in gene‐silencing technology

Recent Advances in Oligonucleotide-Based Therapy for Transthyretin Amyloidosis: Clinical Impact and Future Prospects

Contact Info

Product

Resources

About